[{"address1": "730 Third Avenue", "address2": "9th Floor", "city": "New York", "state": "NY", "zip": "10017", "country": "United States", "phone": "781 419 1400", "website": "https://syndax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.", "fullTimeEmployees": 270, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael A. Metzger M.B.A.", "age": 53, "title": "CEO & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1240515, "exercisedValue": 0, "unexercisedValue": 2486503}, {"maxAge": 1, "name": "Mr. Keith Alan Goldan CPA", "age": 53, "title": "CFO, Treasurer & Chief Accounting Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 736241, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Luke J. Albrecht J.D.", "age": 45, "title": "Senior VP, General Counsel & Secretary", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 703548, "exercisedValue": 0, "unexercisedValue": 849690}, {"maxAge": 1, "name": "Mr. Steven  Closter", "age": 55, "title": "Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 687255, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Ordentlich B.Sc., Ph.D.", "age": 55, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard A. Heyman Ph.D.", "age": 67, "title": "Co-Founder", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald M. Evans Ph.D.", "age": 74, "title": "Co-Founder, Advisor and Chair of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Downes Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Sharon  Klahre", "title": "Vice President of Investor Relations & Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McManus", "age": 55, "title": "Chief People Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 16.66, "open": 16.58, "dayLow": 16.42, "dayHigh": 17.265, "regularMarketPreviousClose": 16.66, "regularMarketOpen": 16.58, "regularMarketDayLow": 16.42, "regularMarketDayHigh": 17.265, "payoutRatio": 0.0, "beta": 0.516, "forwardPE": -4.694916, "volume": 2259887, "regularMarketVolume": 2259887, "averageVolume": 2681734, "averageVolume10days": 3434070, "averageDailyVolume10Day": 3434070, "bid": 12.25, "ask": 21.28, "bidSize": 2, "askSize": 2, "marketCap": 1447565824, "fiftyTwoWeekLow": 8.58, "fiftyTwoWeekHigh": 18.0, "allTimeHigh": 29.86, "allTimeLow": 3.39, "priceToSalesTrailing12Months": 13.005515, "fiftyDayAverage": 15.2777, "twoHundredDayAverage": 13.037425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1335781632, "profitMargins": -2.7993302, "floatShares": 77838321, "sharesOutstanding": 86914838, "sharesShort": 25344944, "sharesShortPriorMonth": 22807077, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.2916, "heldPercentInsiders": 0.0128, "heldPercentInstitutions": 1.20193, "shortRatio": 7.99, "shortPercentOfFloat": 0.32889998, "impliedSharesOutstanding": 87097817, "bookValue": 1.328, "priceToBook": 12.515061, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -311576992, "trailingEps": -3.6, "forwardEps": -3.54, "enterpriseToRevenue": 12.001, "enterpriseToEbitda": -4.353, "52WeekChange": 0.03165734, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 16.62, "targetHighPrice": 56.0, "targetLowPrice": 22.0, "targetMeanPrice": 38.30769, "targetMedianPrice": 38.0, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 454174016, "totalCashPerShare": 5.226, "ebitda": -306897984, "totalDebt": 345431008, "quickRatio": 4.355, "currentRatio": 4.64, "totalRevenue": 111304000, "debtToEquity": 299.256, "revenuePerShare": 1.286, "returnOnAssets": -0.39242, "returnOnEquity": -1.29322, "grossProfits": -133228000, "freeCashflow": -196095872, "operatingCashflow": -310880000, "revenueGrowth": 2.67, "grossMargins": -1.19697, "ebitdaMargins": -2.7573001, "operatingMargins": -1.2519001, "financialCurrency": "USD", "symbol": "SNDX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Syndax Pharmaceuticals, Inc.", "longName": "Syndax Pharmaceuticals, Inc.", "epsTrailingTwelveMonths": -3.6, "epsForward": -3.54, "epsCurrentYear": -3.03811, "priceEpsCurrentYear": -5.4705067, "fiftyDayAverageChange": 1.3423004, "fiftyDayAverageChangePercent": 0.08786011, "twoHundredDayAverageChange": 3.5825758, "twoHundredDayAverageChangePercent": 0.27479166, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1763168357, "regularMarketTime": 1763154000, "exchange": "NMS", "messageBoardId": "finmb_27240138", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": -0.24009, "regularMarketPrice": 16.62, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1456929000000, "postMarketChangePercent": 1.8050494, "postMarketPrice": 16.92, "postMarketChange": 0.29999924, "regularMarketChange": -0.039999, "regularMarketDayRange": "16.42 - 17.265", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2681734, "fiftyTwoWeekLowChange": 8.040001, "fiftyTwoWeekLowChangePercent": 0.93706304, "fiftyTwoWeekRange": "8.58 - 18.0", "fiftyTwoWeekHighChange": -1.3799992, "fiftyTwoWeekHighChangePercent": -0.07666662, "fiftyTwoWeekChangePercent": 3.1657338, "earningsTimestamp": 1762203600, "earningsTimestampStart": 1762203600, "earningsTimestampEnd": 1762203600, "earningsCallTimestampStart": 1762205400, "earningsCallTimestampEnd": 1762205400, "isEarningsDateEstimate": false, "displayName": "Syndax Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]